WEBULL
WebtradeDownload

Nippon Care Supply (TSE:2393) Stock Cools As Premium Valuation Draws Focus

Simply Wall St · 3d ago

Nippon Care Supply stock has cooled off after a strong three month run, with the share price down about 10% over the past month even before investors processed this latest report. The quarterly headline does not scream disappointment. Revenue for Q1 2027 came in at ¥9,193m with net income of ¥545m, and trailing earnings per share now sit at ¥150.52. The real tension for you as an investor is that these earnings sit against a P/E of 25.8x, which is far richer than Japan healthcare peers, so every quarter now has to justify that premium.

Is Nippon Care Supply really priced for its 25.8x P/E, or is the stock quietly edging past what recent earnings support? Compare the market’s optimism with the underlying cash flows in the valuation analysis for Nippon Care Supply

Q1 2027 Earnings Summary

  • Revenue (Q1 2027 vs Q1 2026): ¥9,193m vs. ¥8,499m (up about 8.2%)
  • Net Income (Q1 2027 vs Q1 2026): ¥545m vs. ¥464m (up about 17.5%)
  • Basic EPS (Q1 2027 vs Q1 2026): ¥35.07 vs. ¥29.86 (up about 17.4%)
  • Trailing Net Profit Margin (Last 12 Months vs Prior Year): 6.6% vs. 5.8% (expanded by 0.8 percentage points)

Prefer clean charts instead of another dense block of numbers about Nippon Care Supply? See the company’s full financial picture with a simple visual view of its valuation in the company report for Nippon Care Supply.

TSE:2393 Trailing 12-Month Earnings & Revenue History as at Jul 2026
TSE:2393 Trailing 12-Month Earnings & Revenue History as at Jul 2026

Steady Nippon Care Supply growth supports defensive angle

For investors leaning toward the “demographic defensive” view on Nippon Care Supply, these Q1 2027 figures broadly line up with that story. Revenue and net income are both higher than a year ago, and trailing net margin has widened to 6.6% from 5.8%. That points to a business that is not just holding its ground but gradually improving profitability. Compared with a three month share price gain of about 75%, the operations look more like a slow and steady compounder than a speculative swing.

Recent share pullback highlights lingering downside questions

The last month tells a more cautious story for Nippon Care Supply. The share price is down about 10% over 30 days and about 2.5% over the past week. That sits awkwardly next to the healthier Q1 2027 earnings and margin trend. It suggests some investors still worry about regulation, pricing pressure or growth limits in welfare equipment and care services. The quarter does not remove those concerns. It indicates instead that any immediate stress is not yet visible in the headline income statement.

After a 75% three month surge and a recent 10% pullback, is this volatility an isolated wobble or an early signal of deeper issues? Review our independent risk analysis for Nippon Care Supply which shows 1 important warning sign

Stay Ahead With Simply Wall St

If Nippon Care Supply’s mix of a 75% three month share price move, a recent 10% pullback and a 25.8x P/E has your attention, register for free with Simply Wall St and add it to a Watchlist to keep an eye on price versus fair value and wait for a setup that suits you. Once you decide to take a position, use the Portfolio Command Center to cut through day to day noise and focus on the key updates that matter to your holdings. For a longer term view, compare your thinking with thousands of other investors through the Community and see what different perspectives highlight. By spotting potential catalysts and risks early, you give yourself a better chance of staying ahead of the market.

Seeking Alternatives Beyond Nippon Care Supply

Fresh ideas move fast. Some stocks build quiet momentum, others approach breakout levels, and a few are already flying under the radar for now. Do not get caught reacting late, get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.